This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Federal University of Rio Grande Do Sul, University of São Paulo, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2016-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2016-2019
Title: Antonio Waldo Zuardi: Innovator in Cannabinoid Research
Introduction
Antonio Waldo Zuardi is a prominent inventor based in Ribeirao Preto, Brazil. He has made significant contributions to the field of cannabinoid research, particularly in the development of fluorinated CBD compounds. With a total of three patents to his name, Zuardi's work has implications for the preparation of medicaments.
Latest Patents
Zuardi's latest patents focus on fluorinated CBD compounds, compositions, and their uses. The inventions relate to fluorine-substituted CBD compounds and their applications in the preparation of medicaments. This innovative approach aims to enhance the therapeutic potential of CBD through chemical modifications.
Career Highlights
Throughout his career, Zuardi has been associated with esteemed institutions such as the Federal University of Rio Grande do Sul (UFRGS) and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work in these organizations has allowed him to explore the medicinal properties of cannabinoids and contribute to scientific advancements in this area.
Collaborations
Zuardi has collaborated with notable figures in the field, including Raphael Mechoulam and Flavio Pereira Kapczinski. These partnerships have enriched his research and expanded the impact of his inventions.
Conclusion
Antonio Waldo Zuardi's innovative work in cannabinoid research, particularly with fluorinated CBD compounds, showcases his commitment to advancing medical science. His contributions continue to influence the development of new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile